Atrial fibrillation: practical aspects of rhythm control medication
Clinical review for general practice · 21.07.2026 · 7 (6) · 46-59
DOI: 10.47407/kr2026.7.6.00862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 21.07.2026. Verfasst von Alexey V Tarasov und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Atrial fibrillation (AF) represents the most prevalent supraventricular tachycardia that is associated with the increase in the rate of cardiovascular complications and mortality. The current patient management paradigm is shifted from the “rate control” strategy to the early proactive “rhythm control”, which is confirmed by large-scale randomized trials and current European and Russian guidelines. The review considers pathophysiological basis of arrhythmogenesis in AF, including electrical, mechanical, structural, and autonomic atrial remodeling levels, as well as the key mechanisms underlying arrhythmia initiation and maintenance (ectopic beat, re-entry, trigger activity/delayed afterdepolarizations). Special attention is paid to the pharmacological rhythm control strategy involving the use of Vaughan-Williams class I and III antiarrhythmic agents: molecular targets, pharmacokinetics, clinical efficacy, and safety profile of propafenone, flecainide, lappaconitine hydrobromide (Allapinin), ethacizine, amiodarone, sotalol, etc. are analyzed, including the drugs available mainly in Russia. It is emphasized that propafenone and flecainide are the globally best studied representatives of the IC class featured prominently in the ESC and ACC/AHA guidelines, while Allapinin and ethacizine are used mainly in Russia and CIS countries and are not included in international guidelines due to the lack of large-scale randomized trials. Based on the current data and guidelines, an algorithmic approach to the anti-relapse therapy selection considering the patient’s phenotype (paroxysmal or persistent AF, structural myocardial abnormality, heart failure, coronary artery disease, left ventricular hypertrophy), atrial remodeling level, conduction system features, comorbidity, and drug interaction is proposed. Principles of antiarrhythmic therapy during the early period after cardioversion and after pulmonary vein isolation as part of the hybrid strategy (invasive + drug treatment) are discussed separately. The review presented is intended for practitioners in cardiology and arrhythmia care and is aimed to make personalization of antiarrhythmic agent selection within the framework of safe and effective rhythm control strategy in AF less complex. Keywords: antiarrhythmic therapy, atrial fibrillation, rhythm control, anti-relapse therapy, antiarrhythmic agents, class IС, class III, catheter ablation, comorbidity.
Zitieren
APA
Tarasov, A. V., Tarasov, A. V., Kazantseva, E. V., & Kazantseva, E. V. (2026). Atrial fibrillation: practical aspects of rhythm control medication. Clinical review for general practice, 7(6), 46-59. https://doi.org/10.47407/kr2026.7.6.00862
Vancouver
Tarasov AV, Tarasov AV, Kazantseva EV, Kazantseva EV. Atrial fibrillation: practical aspects of rhythm control medication. Clinical review for general practice. 2026;7(6):46-59. doi:10.47407/kr2026.7.6.00862
BibTeX
@article{Tarasov2026,
author = {Tarasov, Alexey V and Tarasov, Alexey V and Kazantseva, Evgeniya V and Kazantseva, Evgeniya V},
title = {Atrial fibrillation: practical aspects of rhythm control medication},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {6},
pages = {46--59},
doi = {10.47407/kr2026.7.6.00862}
}
EUVIMED